Observer-blind, Randomized, Controlled Study to Determine the Immunogenicity and Safety of a Two-dose Regimen of Virosomal Subunit Influenza Vaccine Inflexal V in Healthy Young Children (greater than or equal 6 Months to less than or equal to 35 Months) in Comparison With the Subunit Influenza Vaccine Agrippal.
Phase of Trial: Phase III
Latest Information Update: 17 May 2013
At a glance
- Drugs Influenza virus vaccine liposomal (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- 15 Mar 2011 New trial record